Freenome IPO

freenome.com

Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Founded2014
Total Funding to Date$1.1B
Register for Details

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Freenome Ticker Symbol

Freenome does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Freenome Stock Price

The stock price for Freenome will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Freenome

Fidelity Investments
Andreessen Horowitz
GV
Polaris Partners
Perceptive Advisors
Kaiser Permanente Ventures

Freenome Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
1/11/2022 Series E $290MM raised $XXX.XX $XXX.XX
12/7/2021 Series D $300MM raised $XXX.XX $XXX.XX
8/26/2020 Series C $270MM raised $XXX.XX $XXX.XX
7/24/2019 Series B $165MM raised $XXX.XX $XXX.XX
8/28/2017 Series A $69.62MM raised $XXX.XX $XXX.XX
6/19/2016 Series Seed-2 $5.55MM raised $XXX.XX $XXX.XX
5/6/2016 Series Seed-1 $800.02K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Freenome in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector